Evidence map›Paper›PMID 42349316›Full record

ReviewTranslational oncology2026

PD-1/PD-L1 immune checkpoint inhibitors in Hodgkin lymphoma: A meta- and network meta-analysis.

Tingxi Zhu, Zhongyu Liu, Huan Sun, Tianchi Lin, Zhe Lu, Xiaoyan Yang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tingxi ZhuWest China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, 610000, China; Med-X Center for Informatics, Sichuan University, Chengdu, 610000, China.
Zhongyu LiuWest China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, 610000, China; Med-X Center for Informatics, Sichuan University, Chengdu, 610000, China.
Huan SunMental health center, West China Second University Hospital, Sichuan University, Chengdu, 610000, China.
Tianchi LinPittsburgh Institute, Sichuan University, Chengdu, 610000, China.
Zhe LuPittsburgh Institute, Sichuan University, Chengdu, 610000, China.
Xiaoyan YangWest China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, 610000, China; Med-X Center for Informatics, Sichuan University, Chengdu, 610000, China. Electronic address: yangxiaoyan@scu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHodgkin lymphoma (HL) is a relatively rare lymphoid malignancy that significantly affects the health of adolescents, young adults and the elderly. Even though conventional chemotherapy offers high cure rates, the relapsed/refractory HL remains challenging.

methodsPooled single-arm and network meta-analyses were used. Literature search was conducted in PubMed, Embase, Web of Science, the Cochrane Library and Clinical Trials, et al., from the date of establishment dates to August 31, 2025. Studies were screened based on inclusion and exclusion criteria. The primary outcome analyzed was complete response rate (CRR), partial response rate (PRR), and objective response rate (ORR).

results11 single-arm trials and five controlled trials, involving 1602 participants and seven ICI-based treatment strategies were included. The meta-analysis revealed an overall CRR of 0.35, a PRR of 0.37, and an ORR of 0.75 across all therapy methods. Of these, one ICI drug in combination with conventional therapy demonstrated the highest CRR and ORR, while camrelizumab achieved the highest PRR. The treatment strategies with the highest CRR in network meta-analysis was the combination of two ICI drugs. The strategies with the highest PRR were camrelizumab, a single ICI drug, while the strategies with the highest ORR was a single ICI drug combined with conventional therapy.

conclusionThis study suggests that camrelizumab is associated with an improved PRR for HL, whereas, combination strategy of two ICI drugs, and that one of pembrolizumab and camrelizumab combined with conventional chemoradiotherapy are more effective for elevating the CRR and ORR respectively.

Indexed as

CamrelizumabHodgkin lymphomaNetwork meta-analysisPD-1/PD-L1 immune checkpoint inhibitorsPembrolizumab

Identifiers

PMID42349316
PMCPMC13316702

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.